MINNEAPOLIS, July 15, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced a strategic partnership to distribute Spear Bio's next-generation ultrasensitive immunoassays, enabling the detection of low-abundance biomarkers in neurology. Under the agreement, Bio-Techne will distribute Spear Bio's ultrasensitive immunoassays for challenging low-abundance biomarkers, including key Alzheimer's disease biomarkers such as phosphorylated tau 217 (pTau 217), GFAP, neurofilament light (Nf-L), and ...

Core Insights - Bio-Techne Corporation is advancing its strategy to enhance patient care through RNAscope technology, focusing on biomarker detection and pathology laboratory workflows [1][2] - The company will showcase these advancements at the USCAP Annual Meeting, highlighting the potential of RNAscope technology in clinical and translational research [1][2] Company Overview - Bio-Techne Corporation is a global life sciences company that provides innovative tools and bioactive reagents for research and clinical diagnostics, generating approximately $1.2 billion in net sales in fiscal 2024 [3] - The company employs around 3,100 individuals worldwide and offers a vast portfolio of products to assist in scientific investigations and drug discovery [3] Technology and Applications - RNAscope technology is being utilized by leading pathologists to detect clinically relevant biomarkers, which may improve performance and reduce time to results compared to existing methods [2][4] - Specific applications of RNAscope technology include the detection of TRIM63 mRNA in renal cell carcinoma, albumin mRNA in liver tumors, and point mutations in gynecologic tumors [4]